Correlation Engine 2.0
Clear Search sequence regions

  • bevacizumab (3)
  • biologics (7)
  • cornea (6)
  • humans (1)
  • nucleic acids (1)
  • peptides (1)
  • products (2)
  • Sizes of these terms reflect their relevance to your search.

    Biologics, like peptides, proteins and nucleic acids, have proven to be promising drugs for the treatment of numerous diseases. However, besides the off label use of the monoclonal antibody bevacizumab for the treatment of corneal neovascularization, to date no other biologics for corneal diseases have reached the market. Indeed, delivering biologics in the eye remains a challenge, especially at the level of the cornea. While it appears to be a rather accessible tissue for the administration of drugs, the cornea in fact presents several anatomical barriers to delivery. In addition, also intracellular delivery barriers need to be overcome to achieve a promising therapeutic outcome with biologics. This review outlines efforts that have been reported to successfully deliver biologics into the cornea. Biochemical and physical methods for achieving delivery of biologics in the cornea are discussed, with a critical view on their efficacy in overcoming corneal barriers. Copyright © 2021 Elsevier B.V. All rights reserved.


    M Wels, D Roels, K Raemdonck, S C De Smedt, F Sauvage. Challenges and strategies for the delivery of biologics to the cornea. Journal of controlled release : official journal of the Controlled Release Society. 2021 May 10;333:560-578

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 33857565

    View Full Text